{"prompt": "['Carbomer and Carboxymethyleellulose', '209510', 'Clinical Protocol V1.0', 'investigator study master file. Original SAE forms will be retained in the investigator study', 'master file.', 'It is essential to enter the following information:', 'Protocol and subject identifiers', 'Subject demography', 'Description of events, with diagnosis if available', 'Investigator opinion of relationship to study product (or study procedure, if appropriate)', 'Criterion for seriousness.', 'The following are desirable and are of particular relevance for investigator and GSK CH', 'assessment of the SAE report:', 'Date of onset of AE', 'Date AE stopped, if relevant', 'Study product start date', 'Study product end date if relevant', 'Action taken in relation to the study product', 'Outcome if known', 'The SAE form, completed as fully as possible, must be scanned and e-mailed to the GSK CH', 'Clinical Operations Safety Reporting email box with the study number and subject number in', 'the subject line of the email immediately and under no circumstance should this exceed 24', 'hours after study site personnel learn of the event. The investigator will submit any updated', 'SAE data to the Sponsor, immediately and under no circumstance should this exceed 24', 'hours of it being available. The GSK CH Study Manager should also be notified of the situation', 'by telephone or email.', 'Email Serious Adverse Events to:', 'PPD', 'The GSK CH Study Manager or designee will be responsible for forwarding the SAE form to', 'the Case Management Group, Global Clinical Safety and Pharmacovigilance mailbox', '/PPD', ').', 'The initial report will be followed up with more information as relevant, or as requested by the', 'GSK CH study manager.', '10.5', 'Evaluating Adverse Events', '10.5.1', 'Assessment of Intensity', 'The investigator or medically qualified designee will make an assessment of intensity for each', 'AE reported during the study and will assign it to one of the following categories:', 'Mild: An event that is easily tolerated by the subject, causing minimal discomfort and', 'not interfering with everyday activities.', 'Moderate: An event that is sufficiently discomforting to interfere with normal everyday', 'activities', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 42 of 65']['Carbomer and Carboxymethylcellulose', '209510', 'Clinical Protocol V1.0', 'Severe: An event that prevents normal everyday activities.', 'NOTE: An AE that is assessed as severe should not be confused with an SAE. Severe is a', 'category utilized for rating the intensity of an event; and both non-serious AEs and SAEs can', 'be assessed as severe. For example, a headache may be severe (interferes significantly with the', \"subject's usual function) but would not be classified as serious unless it met one of the criteria\", \"for SAEs, listed above. An event is defined as 'serious' when it meets at least 1 of the predefined\", 'outcomes as described in the definition of an SAE, NOT when it is rated as severe.', '10.5.2', 'Assessment of Causality', 'The causality assessment is one of the criteria used when determining regulatory reporting', 'requirements. For each AE (serious and non-serious), the investigator (or medically qualified', 'designee) must provide an assessment of causality on the AE CRF page and the SAE form', '(subject to the classification of the AE). The investigator will also document in the medical', 'notes that he/she has reviewed the AE and assessed causality, where applicable.', 'A', '\"reasonable possibility\" of a relationship conveys that there are facts, evidence, and/or', 'arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.', 'Generally, the facts (evidence) or arguments to suggest a causal relationship should be provided.', 'The investigator will use clinical judgment to determine the relationship and will also consult', 'the Investigator Brochure, Safety Statement and/or Product Information, for marketed products,', 'in the determination of his/her assessment. Alternative causes, such as underlying disease(s),', 'concomitant therapy, other risk factors, and the temporal relationship of the event to the study', 'product will be considered and investigated.', 'For each AE/SAE, the investigator must document in the medical notes that he/she has reviewed', 'the AE/SAE and has provided an assessment of causality.', \"The investigator's assessment of causality must be provided for all AEs (serious and non-\", 'serious); the investigator must record the causal relationship in the CRF, as appropriate, and', 'report such an assessment in accordance with the SAE reporting requirements if applicable.', 'There may be situations when an SAE has occurred and the investigator has minimal', 'information to include in the initial report to GSK. However, it is very important that the', 'investigator always make an assessment of causality for every event prior to the initial', 'transmission of the SAE data to GSK CH. The investigator may change his/her opinion of', 'causality in light of follow-up information and send an SAE follow-up report with the updated', 'causality assessment.', '10.6', 'Follow-up of Adverse Events', 'After the initial report, the investigator is required to proactively follow up with each subject', \"and provide further information on the subject's condition.\", 'All AEs (serious and non-serious) will be followed until resolution, until the condition stabilizes,', 'until the event is otherwise explained, or until the subject is lost to follow-up.', 'The investigator is obligated to perform or arrange for the conduct of supplemental', 'measurements and/or evaluations as may be indicated or as requested by GSK CH to elucidate', 'as fully as possible the nature and/or causality of the AE. This may include additional laboratory', 'tests or investigations, histopathological examinations, or consultation with other health care', 'professionals.', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 43 of 65']\n\n###\n\n", "completion": "END"}